
IPS
2 Projects, page 1 of 1
Open Access Mandate for Publications and Research data assignment_turned_in Project2016 - 2021Partners:Universitäts-Augenklinik Bonn, UOXF, FFM, ILM, WU +53 partnersUniversitäts-Augenklinik Bonn,UOXF,FFM,ILM,WU,FIOCRUZ,EMBL,KUL,University of Glasgow,University Hospital Heidelberg,IASMA,INSERM,INSP,CNRS,NIPH,SOSECALI C.LTDA,Charité - University Medicine Berlin,CEA,ULiege,UIS,IPS,OvGU,FDHA,UMCG,BNI,IRD,MPG,INSERM,UNISI,ERASMUS MC,LUMC,Johnson & Johnson (United States),LNCC,Janssen (Belgium),RENNES 2,Universidad Peruana Cayetano Heredia,INSTITUTE FOR FOOD AND AGRICULTURE RESEARCH AND TE,FUNDACAO BAHIANA DE INFECTOLOGIA,IPNC,UFG,Inserm Transfert,Institut Pasteur,AMU,LSHTM,Institut Pasteur de Dakar,NKI ALV,UZH,UB,NOVA,TiHo,UNIVERSITE LYON 1 CLAUDE BERNARD,ANSES,IMSS,IHMT,IPC,INSTITUTO DE MEDICINA TROPICAL PEDRO KOURI,UFMG,IRBFunder: European Commission Project Code: 734548Overall Budget: 15,694,900 EURFunder Contribution: 11,964,200 EURZIKAlliance is a multidisciplinary project with a global "One Health" approach, built: on a multi-centric network of clinical cohorts in the Caribbean, Central & South America; research sites in countries where the virus has been or is currently circulating (Africa, Asia, Polynesia) or at risk for emergence (Reunion Island); a strong network of European and Brazilian clinical & basic research institutions; and multiple interfaces with other scientific and public health programmes. ZIKAlliance will addrees three key objectives relating to (i) impact of Zika virus (ZIKV) infection during pregnancy and short & medium term effects on newborns, (ii) associated natural history of ZIKV infection in humans and their environment in the context of other circulating arboviruses and (iii) building the overall capacity for preparedness research for future epidemic threats in Latin America & the Caribbean. The project will take advantage of large standardised clinical cohorts of pregnant women and febrile patients in regions of Latin America and the Caribbean were the virus is circulating, expanding a preexisting network established by the IDAMS EU project. I will also benefit of a very strong expertise in basic and environmental sciences, with access to both field work and sophisticated technological infrastructures to characterise virus replication and physiopathology mechanisms. To meet its 3 key objectives, the scientific project has been organised in 9 work packages, with WP2/3 dedicated to clinical research (cohorts, clinical biology, epidemiology & modeling), WP3/4 to basic research (virology & antivirals, pathophysiology & animal models), WP5/6 to environmental research (animal reservoirs, vectors & vector control) , WP7/8 to social sciences & communication, and WP9 to management. The broad consortium set-up allow gathering the necessary expertise for an actual interdisciplinary approach, and operating in a range of countries with contrasting ZIKV epidemiological status.
more_vert Open Access Mandate for Publications assignment_turned_in Project2020 - 2023Partners:ECRIN, UOXF, ERASMUS MC, ICNARC, UMC +11 partnersECRIN,UOXF,ERASMUS MC,ICNARC,UMC,INSERM,IPS,STICHTING RADBOUD UNIVERSITEIT,NIPH,ECRAID,STICHTING AMSTERDAM UMC,Charité - University Medicine Berlin,Institut Pasteur,UAntwerpen,Amsterdam UMC,FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUSFunder: European Commission Project Code: 101003589Overall Budget: 20,590,200 EURFunder Contribution: 19,995,200 EURRECoVER (Rapid European SARS-CoV-2 Emergency Research response) is a comprehensive research response to the SARS-CoV-2 outbreak addressing the most urgent questions for patient and public health level interventions. RECoVER originates from partners of the EU Framework 7 (FP7) funded PREPARE project (Platform for European Preparedness Against (Re-) emerging Epidemics. In RECoVER, we will address these urgent questions in a comprehensive, multidisciplinary and interacting set of research response activities, combing (i) clinical studies in primary and hospital care, (ii) epidemiological studies and modelling, and (iii) clinical biological studies. The proposed studies complement ongoing research in China, addressing key knowledge gaps and patient-cohort questions relevant to the European population. The research proposed includes essential needs for preparedness and response, even if circulation of the virus in Europe will be limited. RECoVER will inform future research response efforts to further strengthen Europe’s and global clinical research preparedness to future emerging infectious diseases.
more_vert